Aptevo Therapeutics Inc. (NasdaqCM: APVO)
Health Care · Biotechnology · US
$1.62
-9.50% today · -94.4% 1Y
Aptevo Therapeutics Inc. (NasdaqCM: APVO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.92M and employs 33 people.
Over the last twelve months the share price has lost 94.4%, trading between 1.37 and 29.70.
Tweenvest scores Aptevo Therapeutics Inc. across four factors: quality 36/100, value 40/100. Its strongest factor is value.
APVO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.92M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -29.72
- Dividend yield
- —
- Beta (5Y)
- 1.68
- 52-week high
- $29.70
- 52-week low
- $1.37
- Avg volume (3M)
- —
- Shares outstanding
- 1.80M
- Employees
- 33
- Next earnings
- —
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
- ISIN
- US03835L7029
- Founded
- 2016
- Listed since
- Jul 20, 2016
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Calidi Biotherapeutics, Inc.NYSEAM: CLDI | $3.09M | $0.84 | -18.74% |
| Restart Life Sciences Corp.CNSX: HEAL | $3.06M | CA$0.07 | -6.67% |
| GRI Bio, Inc.NasdaqCM: GRI | $3.02M | $1.38 | -20.69% |
| Eocene Ltd.NasdaqCM: EOCN | $2.97M | $2.85 | -19.49% |
| Mustang Bio, Inc.NasdaqCM: MBIO | $2.85M | $0.38 | -5.92% |
| BSF Enterprise PlcLSE: BSFA | $2.82M | £0.01 | +0.00% |
| HCW Biologics Inc.NasdaqCM: HCWB | $2.77M | $1.24 | -22.50% |
| Modus Therapeutics Holding AB (publ)OM: MODTX | $2.76M | Skr0.18 | -52.45% |
Figures last refreshed Oct 18, 2026.